Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemí Puig, María‐Teresa Cedena et al.|Journal of Clinical Oncology|2019Cited by 279
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Pérez, Bruno Paiva, Cirino Botta et al.|Blood|2020Cited by 156
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan‐José Garcés, Bruno Paiva, María‐Teresa Cedena et al.|Journal of Clinical Oncology|2022Cited by 114
Mass spectrometry vs immunofixation for treatment monitoring in multiple myelomaNoemí Puig, María‐Victoria Mateos, María-Teresa Contreras et al.|Blood Advances|2022Cited by 53
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical TrialJuan Manuel Rosa-Rosa, Joaquín Martínez‐López, Norma C. Gutiérrez et al.|Cancers|2022Cited by 15